GSK3β <sup>high</sup> /NFATc1 <sup>high</sup> subtype targeting overcomes therapy resistance in pancreatic cancer through transcriptional induction of homologous recombination repair
We have identified a highly aggressive GSK3β<sup>high</sup>/NFATc1<sup>high</sup> subtype that predicts early recurrence, poor survival and cisplatin resistance in PDAC. This subtype reveals new treatment vulnerabilities suggesting that patients with PDAC may benefit from stratification-based tailored treatment strategies.
Authors
- Xuean Liu
- Sercan Mercan
- Ulrich Sax (ORCID: https://orcid.org/0000-0002-8188-3495)
- Holger Bastians (ORCID: https://orcid.org/0000-0001-7915-3648)
- Audrey Weber
- Shiv K. Singh (ORCID: https://orcid.org/0000-0002-5725-4058)
- Zeynab Najafova (ORCID: https://orcid.org/0000-0003-4403-5566)
- K Reutlinger
- Zuriñe Bonilla del Rio (ORCID: https://orcid.org/0000-0001-8997-8459)
- Elisabeth Heßmann (ORCID: https://orcid.org/0000-0002-9462-1291)
- Frederike Penz
- Lukas Klein (ORCID: https://orcid.org/0000-0003-3725-068X)
- Steven A. Johnsen
- O Krämer
- Günter Schneider (ORCID: https://orcid.org/0000-0003-1840-4508)
- Karly Conrads (ORCID: https://orcid.org/0009-0006-4536-8564)
- A Bockelmann
- Jovan Todorović
- Ivan Bogeski
- G. Schmídt
- Philipp Stroebel
- L Huhnold
- Tim Beissbarth
- LC Conradi
- Muhammad Umair Latif
- Volker Ellenrieder
- Ramy Ashry
- Atmika Paul
- Xueyuan Zhao
Institutions
- Mansoura University (EG)
- Johannes Gutenberg University Mainz (DE)
- Robert Bosch Hospital (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Universitätsmedizin Göttingen (DE)
- University of Göttingen (DE)
- Robert Bosch (Germany) (DE)
Publication Details
- Journal
- Gut
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1136/gutjnl-2025-336227
- Primary Topic
- Wnt/β-catenin signaling in development and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00